DXCMDexcom
Price
+16%1YEnd-of-day closes, not the intraday tick.
We are a medical device company primarily focused on the design, development and commercialization of continuous glucose monitoring, or CGM, systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians around the world. We received approval from the Food and Drug Administration, or FDA, and commercialized our first product in 2006. We launched our latest generation systems, the Dexcom G7 Continuous Glucose Monitoring System, or G7, in 2023, and the Dexcom G7 15 Day Continuous Glucose Monitoring System, or G7 15 Day, in late 2025.
In the company’s own words · 10-K filed Feb 12, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Business segments
Q2 2026 · $1.10BThe company’s own SEC segment disclosure.
- United States$893.5M81%
- Non Us$208.9M19%
Dexcom (DXCM) reported revenue of $1.34B in Q3 2026 (quarter ended Sep 30, 2026), up 11% from the same quarter a year earlier. That came with a gross margin of 64% and net income of $275M (20% of revenue). For the full year FY2025, revenue was $4.66B (+16% year on year) and net income $836M. Its largest region in Q2 2026 (quarter ended Jun 30, 2026) was United States at $894M, 81% of the disclosed total, well ahead of Non Us at 19%. The next results filing is expected around Feb 11, 2027, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Oct 29, 2026On October 29, 2026, Dexcom announced that its Board of Directors authorized and approved a share repurchase program of up to $1.0 billion of Dexcom’s outstanding common stock, par value $0.001 per share (“Common Stock”), with a repurchase period ending no later than December 31, 2027 (the “Share Repurchase Program”)Earnings release · Form 8-K
- Sep 14, 2026On September 10, 2026, the Board of Directors (the “Board”) of DexCom, Inc. (“Dexcom” or the “Company”) appointed Jereme Sylvain, the Company’s EVP, Chief Financial Officer, to the role of EVP, Chief Operating Officer and Chief Financial Officer, effective September 14, 2026.Director or officer change · Form 8-K
- Sep 10, 2026On September 10, 2026, the Board of Directors (the “Board”) of DexCom, Inc. (“Dexcom” or the “Company”), pursuant to the Amended and Restated Bylaws of the Company, increased the size of the Board to thirteen directors and appointed Glenn S. Boehnlein as a director, effective immediately.Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Medical Devices
The closest names by size in the same industry